Development of New Pharmacological Agents for Epilepsy: Lessons from the Kindling Model
- 1 March 1989
- Vol. 30 (s1) , S13-S18
- https://doi.org/10.1111/j.1528-1157.1989.tb05809.x
Abstract
Summary: The greatest value of the kindling model for new therapy of epilepsy almost certainly lies in elucidating the molecular basis of its development and persistence. Such an understanding may provide a foundation for therapies aimed at prevention or perhaps even cure of some forms of human epilepsy.Keywords
This publication has 36 references indexed in Scilit:
- Intravenous phenytoin is an effective anticonvulsant in the kindling modelAnnals of Neurology, 1989
- A pharmacological study in the kindling model of epilepsyNeuropharmacology, 1984
- Depletion of noradrenaline fails to affect kindled seizuresExperimental Neurology, 1984
- Pharmacological investigation of gamma-aminobutyric acid (gaba) and fully-developed generalized seizures in the amygdala-kindled ratNeuropharmacology, 1982
- Phencyclidine inhibition of the rate of development of amygdaloid kindled seizuresExperimental Neurology, 1982
- Pharmacological modification of amygdaloid-kindled seizuresNeuropharmacology, 1980
- Anticonvulsant drugs and their antagonism of kindled amygdaloid seizures in ratsNeuropharmacology, 1980
- Effects of γ-acetylenic GABA and γ-vinyl GABA on metrazol-activated, and kindled seizuresPharmacology Biochemistry and Behavior, 1979
- A permanent change in brain function resulting from daily electrical stimulationExperimental Neurology, 1969